Peripheral Blood Stem Cell Graft That Are Cd34+ Selected
Sickle Cell-thalassemia Disease
Catherine BollardCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Sickle Cell-thalassemia Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF) Gamida Cell ltd | Phase 1/2 | CCC |
Hydroxyurea Nova Laboratories Limited | Phase 1/2 | CCC |
Bortezomib M.D. Anderson Cancer Center | Early Phase 1 | C |
Fludarabine M.D. Anderson Cancer Center | Early Phase 1 | C |
Busulphan M.D. Anderson Cancer Center | Early Phase 1 | C |
View all 10 →
Same molecule, other indications
Peripheral Blood Stem Cell Graft That Are Cd34+ Selected is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →